髂静脉支架植入术后药物治疗策略研究进展  

Antithrombotic therapy after iliac vein stenting

作　　者：钟文 楼燕[1] 邱宸阳 李栋林[2] 张鸿坤[2] ZHONG Wen;LOU Yan;QIU Chenyang;LI Donglin;ZHANG Hongkun(Department of Pharmacy,the First Afiliated Hospital,Zhejiang University Schoo of Medicine,Hangzhou 310003,China;Department of Vascular Surgery,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院药学部,浙江杭州310003 [2]浙江大学医学院附属第一医院血管外科,浙江杭州310003

出　　处：《浙江大学学报（医学版）》2020年第1期131-136,共6页Journal of Zhejiang University(Medical Sciences)

基　　金：浙江省科技计划(2019C03013)

摘　　要：近年来支架植入治疗髂静脉狭窄或压迫已有普及趋势,但支架治疗术后抗凝血药和抗血小板药的选择尚无共识。针对非血栓性、急性血栓性和慢性血栓性髂静脉狭窄或压迫这三种不同情况,患者术后用药方案和预后也不尽相同。非血栓性患者无论采用何种抗凝、抗血小板策略,支架通畅率均较满意;急性血栓性患者以抗凝为基础,联用抗血小板药能否额外获益有待进一步探讨;而慢性血栓性患者在不同用药策略下预后均较差。本文就患者术后不同用药方案作一综述,以期为最佳用药策略提供思路。Stenting for iliac vein stenosis or compression has become a common therapeutic approach in recent years.The antithrombotic therapy after the stent deployment,however,reaches no consensus.Medications strategies and patients’prognoses differ in non-thrombotic,acute thrombotic and chronic thrombotic these three circumstances.Non-thrombotic patients usually possess satisfactory stent patency whatever antithrombotic therapy is used.Anticoagulant is the basic medication for acute thrombotic patients,benefits from additional antiplatelet drug remains to be clarified.In terms of chronic thrombotic patients,their prognoses are unsatisfactory under all antithrombotic therapies.In this review,we outlined the recent progress of antithrombotic therapy after iliac vein stenting,aiming to provide feasible medication plans for each circumstance.

关 键 词：髂静脉 支架 手术后 抗凝血药 抗血小板药 综述 

分 类 号：R654.3[医药卫生—外科学] R453.9[医药卫生—临床医学]